# Allergy Therapeutics to Present at the Virtual H.C. Wainwright Global Investor Conference

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-to-present-at-the-virtual-h.c.wainwright-global-investor-conference/4121021468
- Published: 2021-09-09T07:17:29+01:00
- Author: Giles

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical company specialising in allergy vaccines,
today announced that Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief
Financial Officer, and Alan Bullimore, Head of Business Innovation of Allergy Therapeutics,
will present at the Virtual H.C. Wainwright Global Investor Conference taking place
from September 13-15, 2021. The presentation will be made available on-demand for
participants from Monday, 13 September 2021.

A copy of the presentation is available below:

[atl-wainwright-presentation-2021](https://www.directorstalkinterviews.com/wp-content/uploads/2021/09/atl-wainwright-presentation-2021.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2021/09/atl-wainwright-presentation-2021.pdf)

Allergy Therapeutics is an international commercial biotechnology company focussed
on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy
vaccines that have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European countries and 
via distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree and house dust
mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in development.

Share on: